Full Press Release Details
Aytu BioScience Provides Update on its Licensed COVID-19 IgG/IgM
Rapid Test Supply and Ongoing U.S. Distribution
Company Places Third Purchase Order for One Million
CO / ACCESSWIRE / April 15, 2020 / Aytu BioScience, Inc. (NASDAQ:
AYTU), a specialty pharmaceutical company focused on
commercializing novel products that address significant patient
needs today provided an update on the supply and distribution of
the company's licensed COVID-19 IgG/IgM Rapid Test. The
company has sold or allocated the initial 100,000 tests to U.S.
customers and is awaiting delivery of the next 500,000
the company has increased the size of its third purchase order to
one million tests. The company has been informed the order has been
accepted by the manufacturer.
Disbrow, Chief Executive Officer of Aytu BioScience, commented,
The company has been working on multiple fronts to
distribute the initial shipment of COVID-19 IgG/IgM Rapid Tests
while coordinating the incoming supply of our next shipment of
500,000 tests. We are pleased that the manufacturer has completed
this second order, which is now awaiting customs clearance.
Further, we have been informed the manufacturer has accepted
another purchase order, which was increased to one million tests.
We are proud to be helping the medical community in delivering our
initial shipment of tests to those professionals in need. We look
forward to having additional supply to further fulfill the
significant demand we have for COVID-19 tests. With the 500,000
tests now awaiting clearance, we'll be in a position to
fulfill the pending orders very soon.
About Aytu BioScience, Inc.
BioScience is a commercial-stage specialty pharmaceutical company
focused on commercializing novel products that address significant
patient needs. The Company currently markets a portfolio of
prescription products addressing large primary care and pediatric
markets. The primary care portfolio includes (i) Natesto , the
only FDA-approved nasal formulation of testosterone for men with
hypogonadism (low testosterone, or "Low T"), (ii) ZolpiMist ,
the only FDA-approved oral spray prescription sleep aid, and (iii)
Tuzistra XR, the only FDA-approved 12-hour codeine-based
antitussive syrup. The pediatric portfolio includes (i)
AcipHex Sprinkle , a granule formulation of rabeprazole
sodium, a commonly prescribed proton pump inhibitor; (ii) Cefaclor,
a second-generation cephalosporin antibiotic suspension; (iii)
Karbinal ER, an extended-release carbinoxamine
(antihistamine) suspension indicated to treat numerous allergic
conditions; and (iv) Poly-Vi-Flor and Tri-Vi-Flor , two
complementary prescription fluoride-based supplement product lines
containing combinations of fluoride and vitamins in various for
infants and children with fluoride deficiency. Aytu recently
acquired exclusive U.S. distribution rights to the COVID-19 IgG/IgM
Rapid Test. This coronavirus test is a solid phase
immunochromatographic assay used in the rapid, qualitative and
differential detection of IgG and IgM antibodies to the 2019 Novel
Coronavirus in human whole blood, serum or plasma.
recently acquired Innovus Pharmaceuticals, a specialty
pharmaceutical company commercializing, licensing and developing
safe and effective consumer healthcare products designed to improve
men's and women's health and vitality. Innovus commercializes over
thirty-five consumer health products competing in large healthcare
categories including diabetes, men's health, sexual wellness and
respiratory health. The Innovus product portfolio is commercialized
through direct-to-consumer marketing channels utilizing the
Company's proprietary Beyond Human marketing and sales
strategy is to continue building its portfolio of
revenue-generating products, leveraging its focused commercial team
and expertise to build leading brands within large therapeutic
markets. For more information visit aytubio.com and visit
innovuspharma.com to learn about the Company's consumer healthcare
Contact for Media and Investors: